Welcome to our dedicated page for Neogenomics news (Ticker: NEO), a resource for investors and traders seeking the latest updates and insights on Neogenomics stock.
NeoGenomics Inc (NEO) provides cutting-edge cancer diagnostic testing and clinical consultation services to healthcare providers worldwide. This news hub delivers timely updates on the company’s advancements in molecular oncology, regulatory milestones, and strategic partnerships shaping precision medicine.
Access authoritative coverage of NEO’s latest developments, including new test launches, laboratory accreditations, and peer-reviewed research insights. Investors and clinicians will find curated updates on earnings reports, biomarker discovery initiatives, and collaborations with leading cancer centers.
Key content areas include regulatory filings, technology partnerships, clinical study outcomes, and executive leadership updates. All news is vetted for accuracy and relevance to oncology professionals and stakeholders in precision diagnostics.
Bookmark this page for streamlined access to NeoGenomics’ evolving role in cancer care innovation. Check regularly for objective reporting on developments impacting diagnostic standards and patient outcomes across global healthcare systems.
NeoGenomics (NASDAQ:NEO) has announced the analytical validation of its PanTracer LBx™ assay, a next-generation sequencing liquid biopsy panel for comprehensive pan-solid tumor profiling. The validation study will be presented at the AACR Annual Meeting 2025 in Chicago, along with five additional research abstracts.
PanTracer LBx is a blood-based test analyzing circulating tumor DNA to identify genomic alterations in advanced-stage solid tumors. The validation study demonstrated high performance in identifying key biomarkers like MSI and TMB across multiple cancer types. The company has launched an Evaluation Assessment Program allowing select physicians early access before full commercial release.
Additional presentations at AACR will cover spatial profiling, tumor biology, and genomic co-occurrence, showcasing NeoGenomics' research in areas such as tumor microenvironment characterization, molecular profiling, and renal cell carcinomas.
NeoGenomics (NASDAQ: NEO), a leading oncology diagnostic solutions provider, has scheduled its first quarter 2025 financial results announcement for Tuesday, April 29, 2025, before U.S. markets open. The company will host a webcast and conference call at 8:30 a.m. ET to discuss the results and recent highlights.
Investors can access the live webcast through the company's Investor Relations website at ir.neogenomics.com. For telephone access, participants should dial (888) 506-0062 (domestic) or (973) 528-0011 (international) using access code 603651.
NeoGenomics (NASDAQ:NEO) has successfully completed its acquisition of Pathline, , a CLIA/CAP/NYS-certified laboratory located in New Jersey. The strategic acquisition strengthens NeoGenomics' commercial footprint in the Northeast United States, particularly in the Tri-state area.
The merger aims to expand access to NeoGenomics' comprehensive oncology test menu and enhance service capabilities, with a focus on accelerating growth in molecular and hematology-oncology testing. This development will provide patients and physicians in the region with broader access to NeoGenomics' high-quality laboratory services.
NeoGenomics (NASDAQ: NEO), a leading oncology testing services company, has announced that Tony Zook has officially taken over as Chief Executive Officer. Zook, who has been a member of the company's Board of Directors since 2023, brings over 30 years of experience in diagnostics and biopharma.
Board Chair Lynn Tetrault highlighted Zook's strong understanding of healthcare and his capability to lead NeoGenomics' next growth phase. As CEO, Zook will focus on execution and growth, particularly in the community oncology setting, where approximately 80% of cancer patients receive treatment.
His leadership approach will emphasize operational discipline, strategic partnerships, and expanding access to advanced diagnostics supporting precision medicine. Zook succeeds Chris Smith, who will remain in an advisory role to ensure a smooth transition.
NeoGenomics (NASDAQ:NEO) has promoted Warren Stone from Chief Commercial Officer to President & Chief Operating Officer, effective April 1, 2025. Stone, with over 25 years of experience, will oversee lab operations, data solutions division, and enterprise operations while maintaining his commercial responsibilities.
Under Stone's leadership since November 2022, the Clinical division has achieved eight consecutive quarters of double-digit revenue growth. The current Chief Operations Officer, Melody Harris, will depart in May. Beth Eastland, Senior Vice President of Enterprise Sales, will support Stone and manage enterprise sales functions.
This organizational restructuring aligns commercial and operations teams to enhance agility and leverage the company's portfolio. The leadership team aims to accelerate growth and profitability while focusing on patient and provider experience.
NeoGenomics (NASDAQ:NEO) has announced the acquisition of Pathline, , a CLIA/CAP/NYS-certified laboratory in New Jersey. This strategic move strengthens NeoGenomics' presence in the Northeast U.S., a historically under-penetrated but growing market.
Founded in 2009, Pathline generates approximately 98% of its revenue from Northeast customers, offering comprehensive subspecialty pathology services including histopathology, immunohistochemistry, cytology, cytogenetics, flow cytometry, FISH, and molecular pathology.
The acquisition brings valuable New York State approvals and aims to enhance NeoGenomics' service capabilities in molecular and hematology-oncology testing. The integration is expected to generate substantial annual cost reductions and become accretive to AEBITDA starting in 2026.
NeoGenomics (NASDAQ:NEO), a leading oncology testing services company, has announced its participation in three major upcoming investor conferences in March:
- TD Cowen 45th Annual Health Care Conference in Boston, MA, featuring a fireside chat on March 4 at 1:50 p.m. ET
- Leerink Partners Global Healthcare Conference in Miami, FL, with a fireside chat scheduled for March 11 at 3:30 p.m. ET
- Barclays 27th Annual Global Healthcare Conference in Miami, FL, hosting a fireside chat on March 13 at 9:00 a.m. ET
All sessions will be available via live and archived webcasts through the Investor Relations section of NeoGenomics' website at ir.neogenomics.com.
NeoGenomics (NEO) reported its Q4 and full-year 2024 results, marking its ninth consecutive quarter of double-digit revenue growth. Full-year consolidated revenue increased 12% to $661 million, while Q4 revenue grew 11% to $172 million.
The company's full-year net loss decreased 11% to $79 million, while Q4 net loss increased 7% to $15 million. Full-year adjusted EBITDA showed significant improvement, increasing 1,036% to $40 million. Average revenue per clinical test increased by 5% to $465, driven by higher value tests and strategic reimbursement initiatives.
For 2025, NeoGenomics reaffirmed its guidance, projecting revenue between $735-745 million (11-13% growth) and adjusted EBITDA of $55-58 million (38-45% growth).
NeoGenomics (NASDAQ: NEO) announced it will release its fourth quarter and full year 2024 financial results before U.S. markets open on Tuesday, February 18, 2025. The company will host a conference call and webcast at 8:30 a.m. ET on the same day to discuss the results and recent highlights.
Investors can access the live webcast through the company's Investor Relations website at ir.neogenomics.com. For those joining by phone, the dial-in numbers are (888) 506-0062 (domestic) and (973) 528-0011 (international), with participant access code 167039. A replay of the webcast will be available shortly after the call.
NeoGenomics (NASDAQ:NEO) has announced its financial guidance for 2025 and updated its Long-Range Financial Plan. The company expects total revenues of $735-745 million and adjusted EBITDA of $55-58 million for 2025, representing year-over-year growth of 11-13% and 43-51% respectively from 2024 midpoint guidance.
The company's Long-Range Plan targets include annual revenue growth of 12-13% with NGS growth of ~25% per year, gross margin expansion of 100-150 basis points annually, and adjusted EBITDA improvement of 250-300 basis points per year. NeoGenomics aims to achieve positive cash flow from operations in 2025 and serve more than 1 million patients annually by 2028.
The company plans to retire its 2025 convertible notes maturing on May 1, 2025, using cash on hand.
FAQ
What is the current stock price of Neogenomics (NEO)?
What is the market cap of Neogenomics (NEO)?
